TheraRadar
Data updated: May 26, 2026

DANTRIUM (dantrolene sodium)

Musculoskeletal Approved 1974-01-15

DANTRIUM is indicated for the treatment of Malignant Hyperthermia.

Source: FDA Label • PH HEALTH
4
Indications
--
Phase 3 Trials
2
Priority Reviews
52
Years on Market

Details

Status
Prescription
First Approved
1974-01-15
Routes
ORAL, INJECTION
Dosage Forms
CAPSULE, INJECTABLE

Companies

Active Ingredient: DANTROLENE SODIUM

DANTRIUM Approval History

1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
146 FDA actions from 1974 to 2024 · 2 indication expansions
Apr 2024 SUPPL
Label · Labeling
Jul 2015 SUPPL Priority
Mfg · Manufacturing (CMC)
Mar 2014 SUPPL Priority
Mfg · Manufacturing (CMC)

What DANTRIUM Treats

1 indications

DANTRIUM is approved for 1 conditions since its original approval in 1974. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Malignant Hyperthermia
Source: FDA Label

Drugs Similar to DANTRIUM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

REVONTO
DANTROLENE SODIUM
1 shared
USWM
Shared indications:
Malignant Hyperthermia
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT02829268 results posted 201607006 R21DK113487 Ph 1, Ph 2 completed A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DANTRIUM FDA Label Details

Indications & Usage

FDA Label (PDF)

DANTRIUM is indicated for the treatment of Malignant Hyperthermia.

Track DANTRIUM with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.